Using nemolizumab (Nemluvio) to treat moderate-to-severe prurigo nodularis in adults

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective, multicenter, non-interventional study collecting real-world physician assessments and patient-reported outcomes over about 12 months in adults newly started on nemolizumab. Treatment decisions are made by the treating physician per local labeling and no extra clinic visits or tests are required beyond routine care. The primary effectiveness evaluation focuses on outcomes at Month 6 using investigator and patient-reported measures. A sub-study in selected German and UK sites will collect daily peak pruritus and sleep disturbance scores remotely for the first two weeks.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Participants who, according to the treating physician's decision and in line with the local package label, are newly initiated on nemolizumab (Nemluvio®) for the treatment of PN.
* Participants greater than or equal to (\>=) 18 years of age.
* Participants who signed the written informed consent form (ICF).

Exclusion Criteria:

* Have contraindication(s) for the use of nemolizumab (Nemluvio®) according to the local package label;
* Participants who received treatment with a drug under clinical development/ investigation within 3 months prior to baseline.
* Participants who received nemolizumab previously.
* Participants who are mentally, physically, or linguistically unable to understand the content of the ICF and/or to complete the study questionnaires.

Where it's running

• Galderma Investigational Site # 8893
  Birmingham, Alabama, United States Recruiting
• Galderma Investigational Site # 7077
  Phoenix, Arizona, United States Recruiting
• Galderma Investigational Site # 7060
  Phoenix, Arizona, United States Recruiting
• Galderma Investigational Site # 7067
  Tucson, Arizona, United States Recruiting
• Galderma Investigational Site # 7074
  Corona, California, United States Recruiting
• Galderma Investigational Site # 6836
  Fountain Valley, California, United States Recruiting

+1 more sites. See ClinicalTrials.gov for the full list.

Study contacts

• Study coordinator: Galderma Research and Development
• Email: clinical.studies@galderma.com
• Phone: 817-961-5000

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Nemolizumab vs placebo in Chinese teens and adults with moderate-to-severe atopic dermatitis

  This study tests whether Nemolizumab can help moderate-to-severe atopic dermatitis in Chinese participants aged 12 and up, compared with a placebo.

  Recruiting Phase 3 Galderma R&D · Hangzhou, Zhejiang · NCT07762833

• Skin structure in atopic dermatitis patients treated with nemolizumab assessed by reflectance confocal microscopy

  This study tests whether nemolizumab changes skin structure in adults with moderate-to-severe atopic dermatitis using a noninvasive imaging method.

  Recruiting Hôpitaux Drôme Nord · Romans-sur-Isère, Drôme · NCT07730788

• Nemolizumab for infants with moderate-to-severe atopic dermatitis

  This study tests whether nemolizumab can be safely given to infants aged 6 to under 24 months to help manage moderate-to-severe eczema when topical treatments alone aren’t enough.

  Recruiting Phase 2 Galderma R&D · San Antonio, Texas · NCT07660835

• Nemolizumab for lichen planopilaris

  This will test whether nemolizumab reduces scalp itching and hair loss in adults with lichen planopilaris.

  Recruiting Phase 4 The Skin Center Dermatology Group · New City, New York · NCT07396168

• Nemolizumab for adults with systemic sclerosis

  This trial will test whether nemolizumab can reduce skin thickness in adults with systemic sclerosis over a 52-week treatment period.

  Recruiting at 3 sites Phase 2 Galderma R&D · Ann Arbor, Michigan and 2 other locations · NCT07047690

• Nemolizumab for moderate-to-severe atopic dermatitis in adolescents and adults

  This will try nemolizumab in adolescents and adults with moderate-to-severe atopic dermatitis to see if it improves symptoms and patient-reported outcomes over six months.

  Recruiting at 81 sites Galderma R&D · Birmingham, Alabama and 107 other locations · NCT06988605

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.